| Title | Naltrexone for the treatment of obesity: review and update. | | Author(s) | Lee MW, Fujioka K | | Institution | Scripps Clinic Center for Weight Management, 12395 El Camino Real, Suite 317, San Diego, CA 92130, USA +1 858 794 1250 ; +1 858 794 1244 ; Lee.MichaelMD@scrippshealth.org. | | Source | Expert Opin Pharmacother 2009 Jun 18. | | Abstract | Since their discovery in the brain and gastrointestinal tract nearly 40 years ago, endogenous opioid peptides have been progressively shown to play a role in the regulation of food intake. Animal and human studies regarding opioid peptides and ingestive behavior are reviewed. While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19537999 |
|
